A passive investor reports owning 2.1 million shares in Vanda Pharmaceuticals (VNDA).
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have filed an amended beneficial-ownership report for Vanda Pharmaceuticals Inc. (VNDA). Each entity reported beneficial ownership of 2,096,939 shares, representing 3.47% of the class, as of September 30, 2026. The report details shared voting power over 1,971,025 shares and shared dispositive power over all 2,096,939 shares.
A motion-sickness medicine gets a floating Art Week event on Biscayne Bay
Vanda Pharmaceuticals announced a floating promotional event for its motion-sickness medication, NEREUS, on Biscayne Bay during Miami Art Week. This activation highlights the medication's boat-trial origins and its approval in December 2025 for preventing motion-induced vomiting in adults. NEREUS is available by prescription through pharmacies or its website, with users advised to consult their healthcare provider.
NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week
Vanda Pharmaceuticals is promoting its NEREUS (tradipitant) motion-sickness medication with a unique floating activation on Biscayne Bay during Miami Art Week. The release highlights NEREUS as the first new prescription treatment for motion-induced vomiting in over 40 years, signaling an ongoing commercial push for the drug approved in December 2025. However, the promotional material lacks financial or sales data.
State Street reports 3.01 million shares in a passive Vanda Pharmaceuticals (VNDA) stake.
State Street Corporation has reported a passive 5% stake in Vanda Pharmaceuticals Inc. (VNDA), amounting to 3,010,531 shares as of September 30, 2026. The filing indicates that State Street holds shared voting power over 2,938,155 shares and shared dispositive power over all 3,010,531 shares, with no sole voting or dispositive powers. This disclosure was made via a Schedule 13G filing with the SEC.
Form 4 Vanda Pharmaceuticals Inc: Charles Cliff Duncan (Director) For: 3 November
This article reports on a Form 4 filing for Vanda Pharmaceuticals Inc., specifically detailing an insider transaction by Director Charles Cliff Duncan on November 3. The filing indicates a significant event concerning the company's stock, VNDA.
Vanda Pharmaceuticals director Charles Duncan buys $38,093 in stock By Investing.com
Vanda Pharmaceuticals director Charles Duncan recently purchased $38,093 worth of company stock over three days in early November 2026, acquiring 10,000 shares at weighted average prices between $3.7959 and $3.821. This insider buying occurred while the stock was trading near its 52-week low, and an InvestingPro analysis suggests the shares are undervalued. The company also reported better-than-expected Q3 2026 financial results and reiterated its full-year revenue outlook, with H.C. Wainwright maintaining a "Buy" rating.
Vanda Pharmaceuticals director Charles Duncan buys $38,093 in stock
Vanda Pharmaceuticals director Charles Duncan recently purchased $38,093 worth of company stock over three days in early November 2026, increasing his total holdings to 108,701 shares. These insider transactions occurred while the stock was trading near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The company also reported exceeding Q3 2026 financial expectations and reiterated its full-year revenue outlook.
Vanda Pharmaceuticals to present at multiple healthcare investor conferences in November 2026
Vanda Pharmaceuticals announced its participation in several healthcare investor conferences throughout November 2026, including events in New York City and London. The company will hold fireside chats at the Stifel 2026 Healthcare Conference and Jefferies Global Healthcare Conference, providing updates on its progress and strategies. Live webcasts and archived recordings will be available on Vanda's website.
Two Vanda conference chats may be watched live in November
Vanda Pharmaceuticals (VNDA) announced its participation in five investor conferences during November 2026, held in New York City and London. Two of these events, the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference, will feature fireside chats that can be accessed live via webcast on Vanda's corporate website, with archives available for approximately 30 days. Investors are encouraged to visit the website for more details on these upcoming presentations.
Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
Vanda Pharmaceuticals Inc. announced its participation in five upcoming investor conferences in November 2026, including the Wolfe Research, Stifel, Truist Securities, UBS Global, and Jefferies Global Healthcare Conferences. The company will hold fireside chats at the Stifel and Jefferies conferences, which will be accessible live on Vanda's corporate website. These events aim to engage investors and share updates on the company's developments.
Vanda Pharmaceuticals Inc. (VNDA) Seasonal Returns Chart
This article presents the historical seasonality chart for Vanda Pharmaceuticals Inc. (VNDA), displaying average monthly price returns from 2016 to 2026. It includes current stock performance data, showing the stock's closing and after-hours prices on November 6. The content highlights the stock's recent price changes and provides navigation options for further research.
Weekly Recap: Revenue beats estimates and FDA reviews Quilmiza
Vanda Pharmaceuticals (NASDAQ:VNDA) surpassed Q3 2026 revenue estimates and raised its 2026 guidance above $240 million, despite reporting a net loss. The company is progressing with FDA reviews for Quilmiza, HETLIOZ, and tradipitant, while also planning the Q4 2026 launch of BYSANTI. Positive Phase III results for HETLIOZ and ongoing trials for other drugs underscore Vanda's active pipeline.
D.C.'s Vanda Pharmaceuticals Reports Phase III Results for NEREUS in GLP-1-Induced Vomiting
Vanda Pharmaceuticals announced positive Phase III results for NEREUS (tradipitant) in preventing vomiting associated with GLP-1 receptor agonist therapy, showing a 27% relative reduction in vomiting incidence. The study also demonstrated significant reductions in severe nausea, frequent multi-day vomiting, and extreme vomiting, with NEREUS being generally well tolerated. Vanda plans to submit a supplemental New Drug Application to the FDA, hoping to expand NEREUS's use to improve GLP-1 treatment adherence.
Q3 revenue hits $69.8M at Vanda Pharmaceuticals (VNDA) as nine-month losses widen.
Vanda Pharmaceuticals (VNDA) reported third-quarter revenue of $69.8 million, an increase from $56.3 million a year earlier, but its net loss widened to $22.6 million for the quarter and $133.6 million for the first nine months of 2026. The company saw strong sales growth for Fanapt and the commercial launch of NEREUS, while HETLIOZ sales declined due to generic competition. Vanda is also actively engaged in multiple legal proceedings and clinical development programs for its product pipeline.
VNDA|Vanda Pharmaceuticals Inc|Price:4.000|Chg%:+0.010
Vanda Pharmaceuticals Inc (VNDA) is trading at $4.000, showing a slight increase of 0.25% at market close. The company reported a Q3 2026 revenue growth of 24% with declining expenses, and analysts maintain a "Buy" rating with a target price of $11.75, representing a significant upside. Vanda Pharmaceuticals focuses on developing and commercializing therapies for unmet medical needs, with products like Fanapt, HETLIOZ, and PONVORY, and has several other drugs in its development pipeline.
Vanda Sets $240 Million-Plus 2026 Revenue Goal, Plans Q4 BYSANTI Launch
Vanda Pharmaceuticals Inc. has announced a revenue target of over $240 million for 2026 and plans to launch its new drug, BYSANTI, in the fourth quarter of the same year. The company's third-quarter revenue saw a 24% year-over-year increase, driven by strong performance from Fanapt and early contributions from NEREUS, HETLIOZ, and PONVORY.
Vanda Pharma Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals (NASDAQ: VNDA) reported a 24% year-over-year revenue growth in Q3 2026, primarily driven by Fanapt and the new launch of Nyrius, with operating expenses decreasing by 18% from the previous quarter. The company anticipates the commercial launch of Bisanti in Q4 2026 and has a pending BLA for Quimilza with an FDA decision expected in December, while also pursuing regulatory approvals for Nyrius in GLP-1–induced vomiting and Hetlioz for delayed sleep-wake phase disorder. Vanda Pharma ended the quarter with $140.5 million in cash, emphasizing continued strong momentum for Fanapt and strategic efforts to expand its product portfolio and reduce operating expenses for long-term profitability.
Vanda: Q3 Earnings Snapshot
Vanda Pharmaceuticals Inc. (VNDA) reported a third-quarter loss of $22.6 million, or 37 cents per share, which exceeded Wall Street expectations. The company also posted revenue of $69.8 million, topping analyst forecasts of $65.9 million. Vanda projects its full-year revenue to reach $240 million.
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Vanda Pharmaceuticals (Nasdaq: VNDA) announced strong third-quarter 2026 financial and operational results, with total revenues increasing 24% year-over-year to $69.8 million and operating expenses decreasing by 18% compared to the previous quarter. The company highlighted momentum from Fanapt and early contributions from the NEREUS commercial launch, with anticipated future growth from the upcoming BYSANTI launch and potential approvals for Quimilza and expanded indications for NEREUS and HETLIOZ. Vanda also updated its full-year 2026 revenue guidance to greater than $240 million.
Vanda Pharmaceuticals Inc. (VNDA) Posts Q3 Loss, Updates 2026 Revenue Outlook
Vanda Pharmaceuticals Inc. (VNDA) reported a Q3 2026 net loss of $22.6 million, or $0.37 per share, which was flat year-over-year but a significant improvement from the Q2 2026 loss of $62.5 million. The company updated its full-year 2026 revenue guidance to greater than $240 million, driven by a 24% year-over-year increase in Q3 revenue and an 18% quarter-over-quarter reduction in operating expenses. A key near-term event is the PDUFA date for Quimilza BLA on December 12, 2026, which could provide additional revenue opportunities if approved.
Vanda Pharmaceuticals Inc (VNDA) News, Articles, Events & Latest Updates
Vanda Pharmaceuticals Inc. (VNDA) recently reported its third-quarter 2026 financial results, exceeding revenue estimates despite a reported loss. The company also announced positive Phase 3 results for Nereus, a treatment for GLP-1 induced vomiting, and provided updates on other clinical development programs and upcoming presentations.
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
Vanda Pharmaceuticals Inc. announced positive results from its Phase 3 trial for Nereus, an oral therapy designed to prevent vomiting caused by GLP-1 receptor agonist treatments. The company plans to submit a supplemental New Drug Application to the FDA, aiming to expand Nereus's label to address a critical tolerability issue in the GLP-1 market. The trial demonstrated significant reductions in vomiting incidence and severity, particularly when Nereus was administered preventatively.
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Vanda Pharmaceuticals announced positive results from its Phase III Study 3601 of NEREUS™ (tradipitant) for preventing vomiting induced by GLP-1 receptor agonist therapy. The study showed NEREUS™ significantly reduced overall vomiting, including frequent multi-day and extreme vomiting episodes. Vanda plans to discuss these results with the FDA and prepare a supplemental New Drug Application (sNDA) to support NEREUS™ for this indication, aiming to improve GLP-1 therapy tolerability.
Vanda Pharmaceuticals Inc. Estimates – FWB:VM4
This article provides an overview of Vanda Pharmaceuticals Inc. (FWB:VM4) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates for income statements, balance sheets, cash flow, and valuation metrics, allowing for comparison of actual results with average, high, and low estimates. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.
Vanda Pharmaceuticals Inc. Estimates – BOATS:VNDA
This page provides an overview of Vanda Pharmaceuticals Inc. (VNDA) financial data and analyst estimates, including income statement, balance sheet, cash flow, and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Vanda Pharmaceuticals Inc. (VNDA) stock price, news, quote and history
Vanda Pharmaceuticals Inc. (VNDA) stock closed at $4.05, up 1.00% on October 22, 2026, with a 52-week range of $3.96 to $9.94. The biopharmaceutical company focuses on developing therapies for unmet medical needs, with a pipeline including treatments for neurological and psychiatric disorders. Analysts have an average target price of $11.75 for the stock, with a recent "Buy" rating reiteration from HC Wainwright & Co.
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals Inc. announced it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026, after the market closes. The company will also host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can access the webcast on Vanda's website, with a replay available until November 4, 2026.
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will release its third-quarter 2026 financial results on Wednesday, October 28, 2026, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can access the call via phone or webcast on Vanda's website, with a replay available until November 4, 2026.
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced it will release its third-quarter 2026 financial results on Wednesday, October 28, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss these results and other corporate activities. A replay of the call will be available until November 4, 2026.
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced it will release its third-quarter 2026 financial results after the market closes on Wednesday, October 28, 2026. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and other corporate activities. Investors can access the webcast and replay details on Vanda's website.
Vanda puts VQW-765 on hold: Vanda Pharmaceuticals stock costs EUR 3.64
Vanda Pharmaceuticals has halted its VQW-765 development program after a Phase III study for social anxiety disorder failed to meet its primary endpoint. The stock traded at EUR 3.64 on October 20, 2026, following the clinical setback and a reported 4% year-over-year decrease in second-quarter revenue. The company is now awaiting further analysis of the study data and has upcoming milestones, including an earnings report and an FDA target action date for another drug, imsidolimab.
Vanda puts VQW-765 on hold: what it means for Vanda Pharmaceuticals stock
Vanda Pharmaceuticals has put its VQW-765 program on hold after a Phase III trial for social anxiety disorder failed to meet its primary endpoint. This setback follows positive results for its HETLIOZ program, which offers a separate regulatory opportunity. The company's Q2 2026 revenue of $50.53 million fell short of estimates, and Vanda Pharmaceuticals stock (VNDA) closed at $4.03 on October 16, 2026, with analysts providing a mixed outlook.
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that its experimental anxiety treatment, VQW-765, failed to meet its primary and secondary endpoints in a Phase 3 trial. The drug, intended for acute social anxiety, showed no significant benefit over a placebo in adult participants. This outcome contradicts promising data from an earlier Phase 2 study, leading to a drop in Vanda Pharmaceuticals' stock.
Vanda Pharmaceuticals puts VQW-765 on hold. Vanda Pharmaceuticals stock costs EUR 3.62
Vanda Pharmaceuticals has put its VQW-765 Phase III study on hold after it failed to meet both primary and secondary endpoints in adults with social anxiety disorder. This clinical setback follows a decline in second-quarter 2026 revenue and has impacted the company's stock, which was trading at EUR 3.62. The company's future now largely depends on the commercial performance of existing products and the regulatory progress of its remaining pipeline programs, including upcoming FDA action dates for Quimilza and HETLIOZ.
MILLENNIUM MANAGEMENT LLC Adds to Vanda Pharmaceuticals Inc (VNDA) Position -- Shares Look 25% Undervalued on GF Value
MILLENNIUM MANAGEMENT LLC increased its stake in Vanda Pharmaceuticals Inc (VNDA) by 26.17% on September 30, 2026, purchasing 883,637 shares at $4.91 each. The firm now holds 4,260,038 shares, representing 7.00% of Vanda's traded stock, indicating confidence in the biopharmaceutical company despite its recent underperformance and "Modestly Undervalued" GF Value. While the stock shows weak financial metrics and significant year-to-date declines, its oversold technical conditions and the hedge fund's strategic add suggest potential for contrarian interest in the volatile biotechnology sector.
Vanda pauses social anxiety program after ex-Novartis asset flunks phase 3 study
Vanda Pharmaceuticals has put its social anxiety disorder drug program on hold after its candidate, VQW-765, failed to meet its primary and secondary endpoints in a phase 3 trial. The trial, which focused on women based on earlier data, did not show a significant improvement over placebo, adding to a series of setbacks in the development of social anxiety treatments. VQW-765 was originally developed by Novartis for schizophrenia before Vanda acquired the rights in 2014.
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
Vanda Pharmaceuticals announced that its experimental drug, VQW-765, failed to meet the primary goal of a late-stage study for social anxiety disorder. The drug did not reduce anxiety compared to a placebo in a public-speaking stress test and missed a key secondary goal, leading the company to put the development program on hold for further analysis. Shares of Vanda Pharmaceuticals dropped significantly in extended trading following the news.
Vanda Pharmaceuticals' Late-Stage Study of VQW-765 to Treat Acute Anxiety Fails to Meet Primary Endpoint
Vanda Pharmaceuticals announced that its late-stage study of VQW-765, a candidate for treating acute anxiety, did not meet its primary endpoint. The article, provided by MT Newswires, notes that the company's stock symbol is VNDA. Full details of the study's failure are available to premium subscribers.
A social anxiety drug missed its main goal. Its maker put the program on hold pending analysis.
Vanda Pharmaceuticals announced that its Phase III clinical trial for VQW-765, a drug intended to treat acute anxiety in adults with social anxiety disorder, failed to meet its primary and key secondary endpoints. The study results did not replicate earlier Phase II findings, leading Vanda to put the VQW-765 development program on hold for further analysis. Despite the missed endpoints, the drug was reported to be safe and well tolerated.
Vanda Pharmaceuticals' anxiety drug fails Phase III trial
Vanda Pharmaceuticals announced that its experimental anxiety drug, VQW-765, failed to meet its primary and key secondary endpoints in a Phase III clinical trial for social anxiety disorder. The study, involving 546 adults, did not replicate findings from an earlier Phase II study. The company has put the VQW-765 program on hold pending further analysis of the data.
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Vanda Pharmaceuticals announced that its Phase III clinical study for VQW-765, a treatment for social anxiety disorder, did not meet its primary endpoint. The study, which evaluated VQW-765 for on-demand treatment of acute anxiety, found no statistically significant difference between the drug and placebo. Consequently, the VQW-765 program is on hold pending further analysis of the full dataset.
Vanda Pharmaceuticals (VNDA) Phase III Trial for VQW-765 Misses Primary Endpoint in Social Anxiety Disorder
Vanda Pharmaceuticals (VNDA) announced that its Phase III clinical trial for VQW-765 failed to meet its primary endpoint in treating acute anxiety in adults with social anxiety disorder, leading to the pausing of its development program. The company's financial health is rated as moderate with a GF Score™ of 66/100, showing strengths in valuation but weaknesses in profitability and momentum. Investors should be cautious, considering the company's unprofitability, negative cash flow, mixed guru sentiment, and insider selling.
Three parties report a shared stake with no sole voting power in Vanda Pharmaceuticals (VNDA).
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have each reported a beneficial ownership of 4,260,038 shares in Vanda Pharmaceuticals Inc. (VNDA), representing 7.0% of the class. These entities exercise shared voting and dispositive power over the shares, with no individual party holding sole voting or dispositive power. The disclosure specifies that the securities are held by entities under the investment discretion of Millennium Management LLC and/or other managers controlled by Millennium Group Management LLC and Israel A. Englander.
Zacks downgrades Vanda Pharmaceuticals stock to Strong Sell
Zacks Research has downgraded Vanda Pharmaceuticals (VNDA) from Hold to Strong Sell. This downgrade follows the company's Q2 2026 revenue of USD 50.53 million and a net loss of USD 62.51 million, though positive Phase III HETLIOZ study results for sleep onset were announced. The stock's current performance shows a decline, and investors await Q3 2026 results on November 4, 2026.
Vanda Pharmaceuticals stock posts positive HETLIOZ trial results
Vanda Pharmaceuticals announced positive Phase III trial results for HETLIOZ, showing a significant shift in sleep onset for patients with delayed sleep-wake phase disorder. Despite a decline in Q2 2026 revenue due to decreased HETLIOZ sales, Fanapt sales rose, and analysts maintain a "Moderate Buy" consensus for Vanda stock, with a high target price significantly above its current trading value. The company plans to discuss the HETLIOZ data with the FDA for a supplemental New Drug Application.
HC Wainwright reaffirms Buy for Vanda Pharmaceuticals stock
HC Wainwright has reaffirmed its "Buy" rating and a $20.00 price target for Vanda Pharmaceuticals (VNDA), indicating a significant upside from its current market valuation. While Vanda Pharmaceuticals reported Q2 2026 revenue of $50.53 million, revenue declined year-over-year and the company posted a widened net loss of $62.51 million. The company's pipeline includes the drug imsidolimab, which has an FDA target action date of December 12, 2026.
HC Wainwright & Co. reiterates Buy rating on Vanda Pharmaceuticals, $20 price target
HC Wainwright & Co. has reiterated its Buy rating for Vanda Pharmaceuticals, setting a price target of $20.00, which suggests a significant upside of 332.0% from its recent closing price. The analyst note highlights the company's strong product portfolio, including HETLIOZ and Fanapt, and its growth potential through market expansion in the US, Europe, and Canada. This positions Vanda Pharmaceuticals as an attractive investment due to its diverse therapies and strategic market focus.
HC Wainwright & Co. reiterates Buy rating on Vanda Pharmaceuticals, $20 price target
HC Wainwright & Co. has reiterated its Buy rating for Vanda Pharmaceuticals, setting a price target of $20.00. This target implies a significant upside of 332.0% from the stock's closing price on October 2nd. The positive outlook is attributed to Vanda's strong product portfolio, including HETLIOZ and Fanapt, and its growth potential in key markets like the United States, Europe, and Canada.
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating for Vanda Pharmaceuticals (VNDA.US) and maintained its price target of $20. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Vanda to present 3 imsidolimab posters at 2026 EADV
Vanda Pharmaceuticals (VNDA) announced it will present three posters on its drug imsidolimab at the 2026 EADV Annual Meeting. The presentations will cover findings from the GEMINI-1 study regarding imsidolimab's effect on neutrophils, its immunogenicity, and its impact on pustulation in patients with generalized pustular psoriasis (GPP). Imsidolimab is an IgG4 monoclonal antibody inhibiting IL-36 receptor signaling and is being developed for the rare orphan indication of GPP.